VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

CAR-TCR Summit Europe 2021 | Allogenic NKX101 in r/r AML

James Trager, PhD, NKarta Therapeutics, South San Francisco, CA describes the ongoing Phase I clinical trial (NCT04623944) of NKX101, an allogeneic NKG2D receptor chimeric antigen receptor (CAR) natural killer (NK) cell therapy, in patients with relapsed/refractory acute myeloid leukemia (AML). The study aims to examine NKX101 monotherapy derived from both human leukocyte antigen (HLA)-matched and unmatched donors in order to investigate the role of HLA matching and the potential of developing a broad, non-matched off-the-shelf program that enables the selection of donors with enhanced NK cell activity and manufacturability. This interview took place during the CAR-TCR Summit Europe 2021.